ARIOUS intrathecally administered drugs have proved to be analgesic in the CCI rat model of neuropathic pain, 4 including N-methyl D-aspartate antagonists, [22] [23] [24] 46, [55] [56] [57] opiates, [55] [56] [57] and ␣ 2 -adrenergic agonists. 19, 56 Intrathecally administered tizanidine, an ␣ 2 -adrenergic agonist, has been shown to produce antinociception 26 and analgesia 35, 50 and to be well tolerated during long-term administration in animals. 32 Human trials of intrathecally administered tizanidine for the treatment of pain have been proposed, 3, 32 emphasizing the importance of studying the underlying pharmacology of the analgesic effect. The analgesia produced by intrathecally administered tizanidine has demonstrated specificity for neuropathic pain signs, leaving acute nociception relatively unaffected.
analgesia was mediated by the ␣ 2A subtype. 43 , 44 Clonidine appears to act through the same receptor subtype as both ST-91 and dexmedetomidine, 45 and there is evidence of mostly an ␣ 2A subtype activity. 13, 21, [42] [43] [44] In rats with experimentally induced neuropathic pain, intrathecally administered ST-91 56 has induced less analgesia for neuropathic pain signs than for acute nociceptive pain signs, whereas tizamidine has produced greater analgesia for neuropathic pain signs than for acute nociceptive pain signs. 19 There is evidence that the ␣ 2B -adrenergic receptor subtype may mediate tizanidine's spinal analgesic effect. 34 In this study, we attempted to determine the subtype of the ␣ 2 -adrenergic receptor that primarily mediates the analgesia produced by intrathecally administered tizanidine in rats with neuropathic pain. To this end, we used the ␣ 1 -adrenergic antagonist prazosin, which is also an ␣ 2B and ␣ 2C subtype-specific antagonist at high concentrations, 8 and the ␣ 1 -adrenergic antagonist WB4101, which is also an ␣ 2A and ␣ 2C subtype-specific antagonist at high concentrations. 28, 29 We compared the effects of prazosin and WB4101 with the effects of yohimbine, a non-subtype-specific, high-affinity ␣ 2 -adrenergic antagonist, to verify the ␣ 2 -adrenergic receptor site of activity. Binding studies found that the chlorpromazine/WB4101 and prazosin/oxymetazoline binding ratios were the best to use for separating and defining the ␣ 2 -adrenergic receptor subtype; however, intrathecally administered chlorpromazine and oxymetazoline were not tolerated by rats in the high concentrations required for this goal. In the present experiment, we used three ␣ 2 -adrenergic antagonists-yohimbine, prazosin, and WB4101-to inhibit the analgesic effect of intrathecally administered tizanidine in the CCI model of neuropathic pain. This study was an attempt to determine which particular ␣ 2 -adrenergic receptor subtype mediates the analgesic effect.
Materials and Methods
The experimental protocol for this study was reviewed and approved by the Animal Care and Use Committee of Northwestern University. Given the complex nature and relative lack of understanding of the mechanisms of neuropathic pain, no adequate alternative to an animal model currently exists to study this debilitating disease process. Every effort was taken to minimize the number of animals that were used to complete this experiment by restricting the number of experimental groups to the minimum number necessary to draw conclusions from the data.
One hundred seventeen male Sprague-Dawley rats (weighing 250-300 g each) were used in the experiment. The chronic neuropathic pain model used in this study was originally described by Bennett and Xie. 4 The rats were given 1 mg/kg atropine subcutaneously and anesthetized with 55 mg/kg sodium pentobarbital administered intraperitoneally. The common sciatic nerve was exposed at the level of the middle thigh by blunt dissection through the biceps femoris muscle. Four loose ligatures of 4-0 chromic gut suture were tied around the nerve at 1-mm intervals. The ligatures were tied to constrict just the surface of the nerve as seen under magnification (ϫ40). The incision was then closed with 4-0 nylon interrupted vertical mattress sutures. The rats were positioned in a stereotactic apparatus for implantation of the intrathecal catheter. Spinal catheterization was performed following the protocol of Yaksh and Rudy. 54 The posterior portion of the head and upper cervical region of the rats were shaved and prepared with betadine solution. Using a No. 11 blade scalpel, we made a midline incision measuring approximately 1 cm from the inion to the upper cervical region. Blunt dissection was performed using the open-scissors technique to dissect through the muscles to the atlantooccipital membrane. Using an 18-gauge needle, we created a small hole in the atlantooccipital membrane; the hole was verified by the release of cerebrospinal fluid. A piece of polyethylene tubing (PE-10) was coated with silicon spray (Siliclad; Clay Adams, Parsippany, NJ) and advanced 8.1 cm from the insertion site to the rostral margin of the lumbar enlargement, through the slit at the atlantooccipital membrane. The catheter was fastened to the skull with dental acrylic. The incision was closed with 4-0 nylon interrupted vertical mattress sutures.
Seven days after the ligation surgery, cold-floor allodynia and pressure hyperalgesia tests were used to verify the generation of signs of neuropathic pain. In the cold-floor ambulation test, symptomatic animals raised their affected hind limbs from the chilled surface on which they were standing as a correlate measure of their cold-related allodynia. The rats were placed on a 0.13-in-thick aluminum floor, which had been chilled to 4˚C by an underlying freezer. This temperature does not evoke pain-related responses from healthy rats. An event recorder was used to measure the frequency In the paw-pinch testing paradigm, rats withdrew their paws from a pinching stimulus as a correlate measure of their hyperalgesia in response to pressure. Increasing pressure was gradually applied to the dorsal side of the affected hind paw by using a graded motor-driven device (Ugo Basile, Milan, Italy). The pressure (in grams) at which limb withdrawal occurred was recorded. Four measurements were obtained at 3-minute intervals so that each paw was tested every 6 minutes. Rats with CCI that exhibited a higher sensitivity in the affected paw during either of these two tests were used in our experiment.
Following a baseline assessment, the animals randomly received a bolus intrathecal injection of 70% dimethyl sulfoxide in saline (vehicle for antagonists); 5, 25, 50, or 100 g prazosin, 5, 23, or 46 g yohimbine; or 5, 45, or 90 g WB4101 in a 10-ml volume. The selection of these doses was based on prior studies in which these antagonists were intrathecally administered. 43, 44 The rats were left alone for 30 minutes to ensure maximal binding of the antagonist, 44 after which they each received a bolus intrathecal injection of 50 g tizanidine in a 10-ml volume. Thirty minutes after the injection, the pain tests were repeated.
Analysis of variance followed by post hoc t-tests were used to determine if the dose-response curves of the three drugs-prazosin, yohimbine, and WB4101-differed to a statistically significant degree. Exponential curves were fit to the data and the IC 50 values for each of the antagonists were determined from the curve formulas.
Results
During the cold-floor ambulation test, yohimbine inhibited the analgesia induced by intrathecally administered tizanidine more than prazosin, and prazosin inhibited the analgesia more than WB4101 (Fig. 1) . Nevertheless, the dose-response curves did not differ to a statistically significant degree (yohimbine compared with prazosin: F(2,32) = 3, p Ͼ 0.05; prazosin compared with WB4101: F(1,19) = 4.4, p Ͼ 0.05).
Regarding the paw-pinch test there were significant differences between the dose-response curves for the affected paw depending on antagonist and dose (Fig. 2) . The doseresponse curve for yohimbine differed from that for prazosin, as demonstrated by ANOVA (F(2,35) = 4.3, p Ͻ 0.05).
According to the post hoc t-test, however, the difference was statistically significant only at 119-nM doses (t = 4.7, p Ͻ 0.001). The dose-response curves for prazosin and WB4101 also differed (F(1,19) = 6.6, p Ͻ 0.05). Again, the post hoc t-tests only showed significance at 119-nM doses (t = 2.9, p Ͻ 0.05).
During the paw-pinch test on the contralateral paw, no baseline analgesia was produced by the intrathecally administered tizanidine. This phenomenon has been consistently observed with intrathecally administered tizanidine in this model of pain when performing these pain tests 19, 20 and, therefore, it could be that there was no inhibition because there was no analgesia to be inhibited (Fig. 3) . The dose-response curves for the various antagonists on the contralateral paw-pinch test were not statistically different (tizanidine compared with prazosin F(2,35) = 1.8, p Ͼ 0.05; prazosin compared with WB4101 F(1,19) = 1.5, p Ͼ 0.05).
The estimated IC 50 values for the three ␣ 2 -adrenergic antagonists were as follows: yohimbine, 9.78 nM; prazosin, 13.6 nM; and WB4101, 92.3 nM. These concentrations were determined by applying logarithmic curves that fit the antagonist data for the affected paw pinch (Fig. 4) . Logarithmic curves were used because they followed a typical pattern of antagonist inhibition; compared with a straight line, the logarithmic curves had the least amount of error in estimating the series of points. The antagonist doses at which the antinociceptive effect of tizanidine was half maximal were calculated using equations for the logarithmic lines. These values were reported as the IC 50 for each antagonist. The Schild regression 16 was used to calculate the equilibrium dissociation constant (pK d for the three antagonists). The calculated pK d s were the following: yohimbine, 0.192; prazosin, 0.248; and WB4101, 47.4.
Discussion
In this study, we used two ␣ 2 -adrenergic receptor subtype-specific antagonists, prazosin and WB4101, and one high-affinity ␣ 2 -adrenergic receptor-specific antagonist,
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Receptor subtype specificity of intrathecal tizanidine analgesia yohimbine, to determine the ␣ 2 -adrenergic subtype specificity of intrathecally administered tizanidine-induced analgesia in the treatment of CCI-related neuropathic pain. The resulting antagonist profiles for the cold-floor ambulation and affected paw-pinch tests were more consistent with the binding profile of the ␣ 2B -adrenergic receptor subtype than those of the ␣ 2A -or ␣ 2C -adrenergic receptor subtype. The antagonists had no significant effect on the contralateral paw-pinch test, but this was expected because at the dose used tizanidine has repeatedly demonstrated no analgesia for pinch on the contralateral normal paw. This test of the contralateral paw pinch serves as a negative control, demonstrating that the antagonists do not have independent effects on the responses to these tests but rather act only as antagonists of tizanidine-induced analgesia. An ␣ 2B -adrenergic receptor subtype specificity for the analgesic effect of intrathecally administered tizanidine in rats with CCI may indicate the possible involvement of dorsal root ganglia because the ␣ 2B -adrenergic receptor subtype is essentially absent in the spinal cord 14, 18, 39, 48 but is present in dorsal root ganglia. 14, 33 The data used for determining receptor subtype involvement came from the paw-pinch test on the affected paw. The first determination was that the analgesic effect of intrathecally administered tizanidine was mediated through ␣ 2 -adrenergic receptors, not ␣ 1 -adrenergic receptors. The dose-response curve of concentrations at which prazosin inhibited intrathecally administered tizanidine-induced analgesia was higher than the dose-response curve for yohimbine. Yohimbine is a specific ␣ 2 -adrenergic antagonist, whereas prazosin is a specific ␣ 1 -adrenergic antagonist. Yohimbine has a much higher affinity for ␣ 2 -adrenergic receptors than for ␣ 1 -adrenergic receptors, and prazosin has a much higher affinity for ␣ 1 -adrenergic receptors than for ␣ 2 -adrenergic receptors. The antagonist effect of yohimbine at much lower doses than prazosin was consistent with an ␣ 2 -adrenergic receptor site of action for the antinociception produced by intrathecally administered tizanidine. These results were consistent with those of many studies of ␣-adrenergic antinociception at the spinal level, which have shown that the effect is mediated by ␣ 2 -adrenergic receptors. 15, 38, 53 A comparison of the IC 50 results for prazosin and WB4101 indicated that the antinociceptive effect of intrathecally administered tizanidine was mediated through the ␣ 2B -adrenergic receptor subtype. Prazosin and WB4101 act as antagonists at ␣ 1 -adrenergic receptors at low doses, but at higher doses they act as antagonists at ␣ 2 -adrenergic receptors. The binding characteristics of prazosin and WB4101 can differentiate between the subtypes of ␣ 2 -adrenergic re- ‡ These values represent constants.
FIG. 5.
Comparison of antagonist ratios from the paw-pinch test and ratios from binding data. The labels 2A, 2B, 2C, 1A, and 1B all refer to the means for the binding ratios of ␣-adrenergic receptor subtypes based on receptor preparations described in the existing literature. Labels 2A, 2B, and 2C are presented with their SEMs. Pawpinch data were obtained from the current study. Data from tail-flick and hotplate tests (asterisks) were obtained from another study in which these antagonists were intrathecally administered and their effects on normal nociception was determined.
ceptors. Prazosin is an ␣ 2A -adrenergic antagonist at lower concentrations than WB4101, and WB4101 is an ␣ 2B -adrenergic antagonist at lower concentrations than prazosin. Both prazosin and WB4101 are ␣ 2C -adrenergic antagonists at intermediate concentrations. Table 1 presents the antagonist profiles of yohimbine, prazosin, and WB4101 with various ␣ 2 -adrenergic receptor preparations.
Because the ␣ 2 -adrenergic receptor subtype can be determined by comparing the concentrations at which these three drugs act as antagonists, the IC 50 ratios for prazosin/yohimbine and WB4101/prazosin were graphed in Fig. 5 . The means and SEMs for the ␣ 2A -, ␣ 2B -, and ␣ 2C -adrenergic receptor preparations were obtained from the existing literature and included along with the ratios of the IC 50 values of the antagonists used in the present study's paw-pinch results.
The majority of the binding data from receptor preparations in the existing literature is presented in the form of inhibitory constants. The formula for the inhibitory constant is K i = IC 50 /(1 ϩ C/K d ), where K i is the inhibitory constant for each antagonist, IC 50 is the concentration of the antagonist that inhibits 50% of agonist activity, C is the concentration of the agonist, and K d is the dissociation constant of the agonist at the receptor. 12 The IC 50 values for the antagonists were calculated from data in this study. Because the agonist was tizanidine for all experimental groups, the C and K d were constant and the ratio of two antagonists' K i values for a given receptor subtype should be the same as the ratio of those two antagonists' IC 50 values for the same receptor subtype. For these reasons, the ratios of the IC 50 values for the antagonists in this study were compared with the ratios of K i values for the same antagonists with standard receptor subtype preparations obtained from the existing literature.
The ratios of the antagonist's effects from this study were plotted on the same graph as the means and SEMs for the ␣ 2A -, ␣ 2B -, and ␣ 2C -adrenergic receptor preparations, which were obtained from the existing literature (Fig. 5) . The pawpinch antinociception produced by intrathecally administered tizanidine had an antagonist binding profile that most closely matched the ␣ 2B -adrenergic receptor subtype antagonist binding profile. The results of the cold-floor ambulation test of allodynia had similar relationships. The antagonist efficacies in descending order were yohimbine, prazosin, and WB4101; however, the differences did not reach statistical significance and did not allow for the calculation of the IC 50 values of the antagonists. We interpreted these results as indicating that the analgesia for neuropathic pain that was induced by intrathecally administered tizanidine was mediated through the ␣ 2B -adrenergic receptor subtype.
In a study by Sagen and Proudfit, 38 the same antagonists used in the present study were intrathecally administered to assess their effects on normal nociception. The hyperalgesic effects produced by intrathecally administered yohimbine, prazosin, and WB4101 were assessed by performing tailflick, radiant heat, and hotplate tests of normal nociception. The IC 50 values for these three antagonists were determined. The calculated ratios of the IC 50 values were 6.51 for the prazosin/yohimbine ratio and 0.485 for the WB4101/prazosin ratio in the tail-flick test and 4.6 for the prazosin/yohimbine ratio and 0.629 for the WB4101/prazosin ratio in the hotplate test. These values were displayed on the graph of ␣ 2A -, ␣ 2B -, and ␣ 2C -adrenergic receptor preparations from the existing literature (Fig. 5) . The antagonist ratio profiles from the tail-flick and hotplate tests most closely resembled the profile of the ␣ 2B -adrenergic receptor subtype. This finding supports the role of the ␣ 2B -adrenergic receptor subtype in spinal antinociception for normal nociceptive pain and indicates that intrathecally administered tizanidine stimulates a normal endogenous pain-control mechanism that is not specific to neuropathic pain.
Noradrenergic projections from brainstem nuclei to the spinal cord dorsal horn are involved in descending antinociception. 36 The receptors on which these projections synapse in the spinal cord are thought to be sites of action for intrathecally administered norepinephrine and ␣ 2 -adrenergic agonists. Various studies, however, have found no significant presence of ␣ 2B -adrenergic receptors in the spinal cord, 14, 18, 39, 48 challenging this paradigm given the findings of the present study. One of two possible explanations could account for this discrepancy.
There could be a change in the expression or binding characteristics of the ␣ 2 -adrenergic receptor subtypes in the spinal cord of rats with the CCI model of neuropathic pain. The studies in which no evidence of an ␣ 2B -adrenergic receptor subtype in the spinal cord were found had been performed in healthy animals with no acute or chronic pain condition. 14, 18, 39, 48 Several studies have shown changes in the spinal cord of animals with neuropathic pain conditions. 2, 30, 52 In the CCI model of neuropathic pain, changes in the expression of spinal cord receptors have been demonstrated, including changes in opiate receptor binding 5, 40 and in the binding affinity of substance P receptors. 1 One possible scenario that could account for the ␣ 2B -adrenergic receptor-mediated antinociception of intrathecally administered tizanidine is that ␣ 2B -adrenergic receptor expression is induced in the spinal cord of rats with CCI through upregulation.
Alternately, intrathecally administered tizanidine analgesia may be mediated through ␣ 2B -adrenergic receptors in dorsal root ganglia. The dura mater and arachnoid extend to cover the dorsal root ganglion, placing it in continuation with the subarachnoid space, 11 and thus the dorsal root ganglion would be exposed to intrathecally administered agents. The ␣ 2B -adrenergic receptor subtype is present in the dorsal root ganglion. 14 Many changes have been found in affected dorsal root ganglia of rats with the CCI model of neuropathic pain. 25, 31, 51 Sympathetic nerve sprouting into the dorsal root ganglion occurs when there is neuropathic pain. 27 These findings support the involvement of the dorsal root ganglion in neuropathic pain. Intrathecally administered tizanidine may produce analgesia by stimulating ␣ 2B -adrenergic receptors in the dorsal root ganglia.
Conclusions
This study has provided evidence that the antinociception produced by intrathecally administered tizanidine is mediated by the ␣ 2B -adrenergic receptor subtype. This is consistent with other reports that tizanidine is an ␣ 2B -adrenergic agonist 34 and that normal endogenous ␣ 2 -adrenergic antinociception is mediated through the ␣ 2 -adrenergic receptor subtype. 38 These findings raise the possibility that the ␣ 2B -adrenergic receptor may be upregulated in the spinal cord of rats with CCI or that intrathecally administered tizanidine acts at the dorsal root ganglion rather than in the spinal cord.
